Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)

Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)

Objectives To report the efficacy, safety and patient-reported outcome measures (PROs) of tofacitinib modified-release 11 mg once daily plus methotrexate in patients with rheumatoid arthritis (RA) from the open-label phase of Oral Rheumatoid Arthritis Trial (ORAL) Shift.Methods ORAL Shift was a glob...

Full description

Bibliographic Details
Main Authors: Boulos Haraoui, Janet Pope, Edward C Keystone, Eduardo Mysler, Tatjana Lukic, Harry Shi, Stanley B Cohen, Rebecca Germino, Lori Stockert, Annette Diehl, Sujatha Menon, Shixue Liu
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/7/2/e001673.full

Internet

https://rmdopen.bmj.com/content/7/2/e001673.full

Similar Items